pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·May 5·1 min read
save

Returning doctors face unexpected hurdles and new chances to improve care in their home countries

May 5, 2026·read at STAT ↗Neutral

The opinion piece argues that the common "brain drain" story about health workers leaving low‑income nations overlooks what happens when they come back.

The author cites a breast surgeon who trained in Ireland and Houston, turned down offers in London and the US, and chose to practice in Dubai. She notes that her return has changed the local case mix, with fewer advanced breast‑cancer patients appearing.

Returning clinicians often have to navigate local constraints such as censorship of medical terminology, limited resources, and the need to create new patient‑education tools. They may also set up support groups or drop‑in centres that fill gaps in the health system.

The article reports that 52 professionals have returned to 43 different countries, encountering both unexpected obstacles and opportunities to improve care and training in their home settings.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: The ‘brain drain’ narrative about health professionals misses half of the story”

read at STAT ↗
1,399 words · retrieved May 5
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
MAIA Biotechnology, Inc.3
drugs
MIFEPRISTONE
topics
Oncology6Breast Cancer3Approval

related stories

  • May 15Opinion: Telehealth abortion with mifepristone continues, with backup plans still in placeSTAT
  • May 8Dr Gruenbaum on Where Alternative Options to BTK Inhibitors Stand in MCLonclive
  • May 7Dr Sznol on Optimal Treatment Sequencing in Melanomaonclive
  • May 7Dr Mauro on the Significance of Alternative TKI Formulations in CMLonclive
  • May 7Dr Olawaiye on the FDA Approval of Relacorilant Plus Nab-Paclitaxel in PROConclive